Recently, an international consensus initiative announced the renaming of PCOS (Polycystic Ovary Syndrome) to PMOS (Polyendocrine Metabolic Ovarian Syndrome).
The change reflects a growing recognition within endocrinology and women’s health research that the condition is far more complex than its previous name suggested.
The term “polycystic ovary syndrome” focused heavily on ovarian morphology.
But PMOS is now understood as a multisystem endocrine-metabolic condition that can involve:
– hormonal dysregulation
– metabolic dysfunction
– reproductive health impacts
– cardiovascular risk factors
– dermatological manifestations
– psychological and quality-of-life effects
Importantly, not all patients diagnosed with the condition present with polycystic ovarian morphology, making the previous terminology increasingly incomplete from a clinical perspective.
The renaming aims to better reflect the systemic and heterogeneous nature of the syndrome.
A broader issue in medicine and epidemiology
The PMOS discussion also highlights a wider challenge in medical research:
Historically, women have been underrepresented in many clinical studies, and sex-specific differences have not always been systematically analyzed.
As a result:
– some diseases were characterized using incomplete population data
– symptom patterns in women were sometimes under-recognized or misclassified
– diagnostic criteria were not always optimized for sex-specific variation
– and certain conditions have experienced long delays in diagnosis and treatment
This is about uneven depth and consistency of evidence across sexes in different fields of medicine.
These gaps are reflected across multiple areas of healthcare, for example:
– Cardiovascular disease: atypical symptom presentation in women may contribute to delayed diagnosis
– ADHD and autism spectrum conditions: diagnostic frameworks have historically been more aligned with male-presenting profiles
– Chronic pain disorders: higher prevalence in women with persistent challenges in recognition and management
– Endometriosis: long diagnostic delays remain common despite high symptom burden
– PMOS: wide phenotypic variability and overlap with metabolic conditions complicate classification and treatment
Modern research is increasingly addressing these limitations through:
– sex-disaggregated analysis of clinical data
– more representative clinical trial design
– improved disease phenotyping
– integration of endocrine, metabolic, and reproductive systems in classification models
– a shift toward precision medicine approaches
These changes are gradually reshaping how conditions are defined
In this context, the renaming of PCOS is not purely semantic.
It reflects how medical knowledge evolves when research becomes more inclusive, more precise, and better aligned with clinical reality.
Could improved classification improve diagnosis, communication, and patient care?